The results of the phase 3 trial EA6134 / DREAMseq, showed a remarkable 20% advantage in the two-year overall survival rate for people with advanced melanoma who first received immunotherapy (72% survival rate) versus those who initially got targeted therapies (52% survival rate). Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on immunotherapy.

DREAMseq was led by Michael Atkins, MD, deputy director of Georgetown Lombardi Comprehensive Cancer Center, on behalf of the ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute.